CoChat

A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model

Open access
Yant, Stephen R., Mulato, Andrew, Hansen, Derek, Tse, Winston C., Niedziela-Majka, Anita, Zhang, Jennifer R., Stepan, George J., Jin, Debi, Wong, Melanie H., Perreira, Jill M., Singer, Eric, Papalia, Giuseppe A., Hu, Eric Y., Zheng, Jim, Lu, Bing, Schroeder, Scott D., Chou, Kevin, Ahmadyar, Shekeba, Liclican, Albert, Yu, Helen, Novikov, Nikolai, Paoli, Eric, Gonik, Daniel, Ram, Renee R., Hung, Magdeleine, McDougall, William M., Brass, Abraham L., Sundquist, Wesley I., Cihlar, Tomas, Link, John O. · 2019 · Nature Medicine
Cited by 154

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

People living with HIV (PLWH) have expressed concern about the life-long burden and stigma associated with taking pills daily and can experience medication fatigue that might lead to suboptimal treatment adherence and the emergence of drug-resistant viral variants, thereby limiting future treatment options1–3. As such, there is strong interest in long-acting antiretroviral (ARV) agents that can be administered less frequently4. Herein, we report GS-CA1, a new archetypal small-molecule HIV capsid inhibitor with exceptional potency against HIV-2 and all major HIV-1 types, including viral variants resistant to the ARVs currently in clinical use. Mechanism-of-action studies indicate that GS-CA1 binds directly to the HIV-1 capsid and interferes with capsid-mediated nuclear import of viral DNA, HIV particle production and ordered capsid assembly. GS-CA1 selects in vitro for unfit GS-CA1-resistant capsid variants that remain fully susceptible to other classes of ARVs. Its high metabolic stability and low solubility enabled sustained drug release in mice following a single subcutaneous dosing. GS-CA1 showed high antiviral efficacy as a long-acting injectable monotherapy in a humanized mouse model of HIV-1 infection, outperforming long-acting rilpivirine. Collectively, these results demonstrate the potential of ultrapotent capsid inhibitors as new long-acting agents for the treatment of HIV-1 infection. A new compound that inhibits HIV capsid assembly and nuclear transport functions offers potential as a long-acting antiretroviral.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0560-x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 154

Metadata

Authors
Yant, S. R., Mulato, A., Hansen, D., Tse, W. C., Niedziela-Majka, A., Zhang, J. R., Stepan, G. J., Jin, D., Wong, M. H., Perreira, J. M., Singer, E., Papalia, G. A., Hu, E. Y., Zheng, J., Lu, B., Schroeder, S. D., Chou, K., Ahmadyar, S., Liclican, A., Yu, H., Novikov, N., Paoli, E., Gonik, D., Ram, R. R., Hung, M., McDougall, W. M., Brass, A. L., Sundquist, W. I., Cihlar, T., & Link, J. O.
Venue
Nature Medicine
Published
2019-09
Volume
25
Issue
9
Pages
1377-1384
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2973091596
Cited by
154
References
11
FWCI
12.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. https://app.cochat.ai/papers/10.1038/s41591-019-0560-x
The paper
Yant, S. R., Mulato, A., Hansen, D., Tse, W. C., Niedziela-Majka, A., Zhang, J. R., Stepan, G. J., Jin, D., Wong, M. H., Perreira, J. M., Singer, E., Papalia, G. A., Hu, E. Y., Zheng, J., Lu, B., Schroeder, S. D., Chou, K., Ahmadyar, S., Liclican, A., . . . Link, J. O. (2019). A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nature Medicine. https://doi.org/10.1038/s41591-019-0560-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.